Meeting report for the ASPET Ray Fuller symposium: Lower urinary tract disorders: Physiology, pharmacology, and therapeutic approaches

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 431-437

  Michel, Martin C ^a,c   Brioni, Jorge D ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; A 119637; A 278637; A 344905; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; CAPSAICIN; DOPAMINE RECEPTOR STIMULATING AGENT; FINASTERIDE; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL AFFECTING AGENT; RO 70 0003; SEROTONIN ANTAGONIST; SILDENAFIL; SSR 240600; STEROID 5ALPHA REDUCTASE INHIBITOR; TACHYKININ RECEPTOR ANTAGONIST; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

BLADDER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ERECTILE DYSFUNCTION; HUMAN; NONHUMAN; PHARMACOPHORE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; URINARY TRACT DISEASE;

HUMANS; IMPOTENCE; MALE; PROSTATIC HYPERPLASIA; URINARY BLADDER DISEASES; UROLOGIC DISEASES;

EID: 0036786403     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.303.1.431     Document Type: Conference Paper

References (0)